What We Do
CSI Singapore conducts basic and translational cancer studies by adopting a multifaceted approach through two strong, multidisciplinary research programs: Cancer Biology & Stem Cell and Experimental Therapeutics. They span the spectrum from laboratory-based studies to targeted therapies in humans, allowing us to harness basic science discoveries to create more effective, as well improve, existing cancer treatments. Our areas of focus lie particularly in gastric, liver, lung and leukemia cancers, which are prevalent in Asian populations, along with a breast cancer working group examining Asian phenotypes.
CSI works closely with basic scientists and clinicians across Singapore in various institutes, including the National University of Singapore (NUS), National University Hospital (NUH), National Cancer Institute Singapore (NCIS), Duke-NUS Graduate Medical School and Institute of Molecular and Cell Biology (IMCB). To accomplish our research goals, we initiated and lead the Frontiers in Cancer Science, an annual cancer conference offering researchers globally a major platform to engage in world-class scientific partnerships.
We house a full spectrum of basic and clinical translational facilities with a multitude of state-of-the-art core support technologies. These sophisticated technologies provide robust investigational resources for CSI and also the wider NUS community.
Situated within the Yong Loo Lin School of Medicine premises in NUS, CSI is located on 3 floors at the Centre for Translational Medicine. It is ideally opposite the 1,000-bed National University Hospital and near other key research institutes such as A*Star at the Biopolis, the Duke-NUS Graduate Medical School and Singapore General Hospital. These locations are easily accessible via Kent Ridge train station just a short walk away from CSI and facilitates the ease of knowledge exchange.